You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.

    SBC: Zena Therapeutics Inc.            Topic: NIDA

    Opioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Team-Based Virtual Field Exercises for HAZMAT Training

    SBC: CELL PODIUM LLC            Topic: R

    Summary/Abstract Among the most educationally valuable components of in-person 40-hour HAZMAT courses are team-based field exercises. This capstone activity combines skills and protocols into an experiential exercise in which learners practice different roles (e.g., entry team, decon team, site supervisor) and equipment (e.g., PPE, sensors, communications). Team-based HAZMAT training exercises hav ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Noncontact Remote Monitoring for the Detection of Opioid-Induced Respiratory Depression

    SBC: AUTONOMOUS HEALTHCARE INC            Topic: NIDA

    The US opioid crisis continues to have a catastrophic impact on human lives and the ongoing COVID-19 pandemic is compounding its effects. Based on the statistics published by the CDC, 91,799 drug overdose deaths occurred in the US in 2020, where the age-adjusted overdose deaths increased by 31% from 2019 to 2020. In addition, opioids, which cause respiratory depression, were involved in 75% of all ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing and testing the Opioid Rapid Response System

    SBC: REAL PREVENTION LLC            Topic: NIDA

    Abstract This Phase II SBIR will develop and demonstrate the efficacy of the Opioid Rapid Response System (ORRS) to improve responses to opioid overdoses. Opioid overdoses exact a tremendous cost in lives and expenditures. Naloxone has been developed to counteract overdoses; however, the nature of these events requires a rapid response, a situation that challenges emergency responders in both ligh ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Integration of non-invasive deep tissue microwave thermometry in the VectRx hyperthermia device in a transgenic liver tumor pig model

    SBC: NeoTherma Oncology Inc.            Topic: 102

    Project Summary/Abstract NeoTherma Oncology (NTO/www.neothermaoncology.com) has developed a novel non-invasive medical device that delivers mild hyperthermia (HT) loco-regionally as adjuvant therapy to standard of care treatment of abdominal deep-seated tumors. The VectRx™ device, designated “Breakthrough” by the FDA, has demonstrated its ability to safely heat abdominal organs (pancreas, li ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Previvors Recharge: A Resilience Program for Cancer Previvors

    SBC: Pro-Change Behavior Systems, Inc.            Topic: 102

    It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Novel hand hygiene product to remove Clostridioides difficile spores

    SBC: Novaflux Inc.            Topic: NIAID

    7. Project Summary/AbstractC. difficile now causes more hospital-onset infections and deaths in the US than any other pathogen and is the most important cause of healthcare-associated diarrhea among adults in industrialized countries. In 2017, there were an estimated 462,100 combined healthcare- and community-associated C. difficile infection cases in the US, and 20,500 in-hospital deaths. In a ra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. End to End, Cold Chain Validation Using Sample Attached History Log

    SBC: BIOTILLION LLC            Topic: OD

    Abstract Regenerative medicine therapies of various kinds are promising and rapidly growing, both in scale and type. The therapeutic products are not pills–they are living cells that are harvested from a patient (or sometimes a cell bank) and are shipped to a pharmaceutical company that modifies the cells and then sends them back to be re- injected into the patient. Logistics plays an outsize r ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups

    SBC: JP LABORATORIES INC            Topic: 300

    Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government